MedTrace Logo

Inflammatory Mediators in Erythema Migrans

NCT03956212 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2020-11-03

No results posted yet for this study

Summary

The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.

Conditions

  • Erythema Migrans

Interventions

DRUG

Doxycycline 7 days

Patient will be treated with doxycycline orally, 100 mg, bid, 7 days

DRUG

Doxycycline 14 days

Patient will be treated with doxycycline orally, 100 mg, bid, 14 days

Sponsors & Collaborators

  • University of Ljubljana School of Medicine, Slovenia

    collaborator OTHER

  • University Medical Centre Ljubljana

    lead OTHER

Principal Investigators

  • Daša Stupica, MD PhD · University Medical Centre Ljubljana

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2019-12-31
Completion
2020-10-31

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03956212 on ClinicalTrials.gov